Latest News

Mirvetuximab soravtansine plus carboplatin showed promise in patients with FRα-positive platinum-sensitive ovarian cancer.

The first patient has been dosed in a phase 1 trial (NCT05997615) of VIR-5500, a dual-masked PSMA-targeting T-cell engager for metastatic prostate cancer.

The DAISY trial shows that HER2DX and DNADX genomic assays can predict T-DXd response in metastatic breast cancer by measuring HER2 levels and DNA instability.

FDA accepted the NDA for 18F-FET, a PET imaging agent designed to distinguish glioma progression from treatment-induced changes in brain cancer.

The novel FRα-targeted ADC sofetabart mipitecan showed strong antitumor activity in patients with heavily pretreated platinum-resistant ovarian cancer.

Trastuzumab pamirtecan, a novel antibody-drug conjugate, showed initial efficacy signals in pretreated patients with HER2-expressing endometrial cancer.

Final ROSELLA overall survival results show adding relacorilant to nab-paclitaxel reduces risk of death by 35% in platinum-resistant ovarian cancer.

Breast cancer surgery myths, new ALK lung drug filing, safer TIL melanoma prep, ovarian ADC fast track, and statins boosting CAR T outcomes.

During a live event, Carol Ann Huff, MD, and participants discussed real-world evidence and personal experiences with talquetamab in relapsed/refractory multiple myeloma.

FDA fully approves brexu-cel CAR‑T for relapsed mantle cell lymphoma, with ZUMA‑2 showing deep responses and key infection-care tips for clinicians.

Learn how G-CSF and trilaciclib help prevent febrile neutropenia in extensive-stage SCLC, with NCCN-backed timing tips and safety notes.

FDA grants fast track designation to SIM0505, a CDH6-targeting ADC, for platinum-resistant ovarian cancer. Phase 1 data expected at ASCO 2026.

Tovecimig plus paclitaxel lifts response rates in second-line biliary tract cancer, prompting FDA orphan status and advancing a potential new option.

The FDA has granted fast track and rolling review status to Celltrion’s CT-P71, a Nectin-4 targeting ADC for treating advanced urothelial carcinoma.

FDA grants orphan drug designation to rhenium (186Re) obisbemeda for pediatric glioma and ependymoma, supported by the phase 1/2a ReSPECT-PBC clinical trial.

New CMML molecular framework links genomic classes and iCPSS scoring to predict outcomes and guide optimal stem cell transplant timing.

During a live event, Paolo Strati, MD and participants explored anti‑CD19 CAR T options for relapsed LBCL—including eligibility and eased REMS rules.

The FDA has agreed on the design of two phase 3 trials of the antibody-drug conjugate CRB-701 in HNSCC and cervical cancer.

Nuvalent has submitted an NDA to the FDA for neladalkib, a brain-penetrant ALK-selective TKI for pretreated advanced ALK-positive NSCLC.

Results of a single-center study showed positive outcomes of reduced-intensity conditioning for tumor-infiltrating lymphocytes in melanoma.

Study finds risk-reducing mastectomy in BRCA1/2 carriers significantly cuts cancer risk but offers no overall survival benefit over intensive surveillance.

Learn the warning signs of renal medullary carcinoma—sickle cell trait, right-sided mass—and why INI1 testing changes therapy and survival.

FDA delays Orca‑T review as plixorafenib earns breakthrough status and ATOMIC/ASTEROID data reshape colon and lung cancer care ahead of key Q2 decisions.

FDA fast track status for CTIM-76 underscores the unmet need in platinum-resistant ovarian cancer.

Statin use alongside CD19 CAR T shows longer survival and less neurotoxicity in relapsed large B-cell lymphoma, prompting calls for trials.

Dr Mehra discussed HPV-positive oropharyngeal cancer, focusing on balancing high cure rates while minimizing toxicity through careful patient selection.

KEYNOTE-564 follow-up shows OS and DFS gains with adjuvant pembrolizumab in high-risk ccRCC, plus guidance on relapse after therapy.

During a live event, Catherine Coombs, MD and participants explored fixed-duration frontline CLL therapies, focusing on patient selection, data gaps, and trade-offs.

New trial data show adding durvalumab/tremelimumab and lenvatinib to TACE delays progression in unresectable HCC, hinting at longer survival.

The FDA granted fast track designation to PAS-004, a macrocyclic MEK inhibitor, for NF1-associated plexiform neurofibromas causing significant morbidity.

Same-day multidisciplinary clinics could shorten time to treatment, boost guideline adherence, and improve satisfaction in solid tumor care, a review finds.